Heart attack

January 23, 2018

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Baicalein, Salidroside and Carnosic acid (BCSSCA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 23/January/2017, 11.30 pm

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Baicalein, Salidroside and Carnosic acid (BCSSCA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 23/January/2017, 11.30 pm https://genomediscovery.org/wp-content/uploads/2018/01/BCSSCA-may-enhance-cardiac-contractility-and-attenuate-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GM-CSF1.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/BCSSCA-may-enhance-cardiac-contractility-and-attenuate-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GM-CSF1.jpg2_.jpg January 23, 2018 January 23, 2018

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

January 22, 2018

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Hesperidin , isolated from blood orange and peppermint, among others, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 23/January/2018, 5.21 am

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Hesperidin , isolated from blood orange and peppermint, among others, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 23/January/2018, 5.21 am https://genomediscovery.org/wp-content/uploads/2018/01/Hesperidin-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/Hesperidin-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg January 22, 2018 January 22, 2018

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

January 22, 2018

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Naringenin, Genesenoside and Fortunellin (NGF) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 23/January/2018, 5.18 am

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Naringenin, Genesenoside and Fortunellin (NGF) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 23/January/2018, 5.18 am https://genomediscovery.org/wp-content/uploads/2018/01/NGF-may-enhance-cardiac-contractility-and-attenuate-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GM-CSF.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/NGF-may-enhance-cardiac-contractility-and-attenuate-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GM-CSF.jpg January 22, 2018 January 22, 2018

January 19, 2018

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing β-Cryptoxanthin, Mangiferin and Glycyrrhetinic acid(CMG)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 19/January/2018, 11.58 pm

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing β-Cryptoxanthin, Mangiferin and Glycyrrhetinic acid(CMG)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 19/January/2018, 11.58 pm https://genomediscovery.org/wp-content/uploads/2018/01/CMG-inhibits-IRF3-GMCSF-and-GRK2-expression-and-attenuates-pathogenesis-associated-with-myocardial-infarction.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/CMG-inhibits-IRF3-GMCSF-and-GRK2-expression-and-attenuates-pathogenesis-associated-with-myocardial-infarction.jpg January 19, 2018 January 22, 2018

January 12, 2018

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Prostaglandin D2 (PGD2), Resveratrol and α-Lipoic acid(PGD2RLA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 12/January/2017, 11.51 pm

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Prostaglandin D2 (PGD2), Resveratrol and α-Lipoic acid(PGD2RLA) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 12/January/2017, 11.51 pm https://genomediscovery.org/wp-content/uploads/2018/01/PGD2RLA-may-enhance-cardiac-contractility-and-attenuate-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GM-CSF.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/PGD2RLA-may-enhance-cardiac-contractility-and-attenuate-pathogenesis-associated-with-myocardial-infarction-through-down-regulation-of-IRF3-GRK2-and-GM-CSF.jpg January 12, 2018 January 12, 2018

January 12, 2018

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture [ANNN] encompassing Aspalathin (AN) and Nothofagin (NN) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 12/January/2018, 11.34 am

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture [ANNN] encompassing Aspalathin (AN) and Nothofagin (NN) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 12/January/2018, 11.34 am https://genomediscovery.org/wp-content/uploads/2018/01/Aspalathin-and-Nathofagin-may-promote-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/01/Aspalathin-and-Nathofagin-may-promote-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg January 12, 2018 January 22, 2018

Popular Post